secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001493152-22-012938
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix Q1 net loss widens to $5.0M; cash $47.5M extends runway to Q2 2024
----------------------------------------------------------------------------

- Net loss of $5.0M ($1.51 per share) vs $4.1M loss in Q1 2021; revenue fell to $1.2M from $1.4M.
- Ended Q1 with $47.5M cash; cash runway extended into Q2 2024, through Pulmazole Phase 2b data readout.
- Pulmazole Phase 2b on track to start dosing Q1 2023; top-line data expected Q2 2024.
- PUR3100 Phase 1 top-line data expected in Q4 2022 from Australian study.
- Completed 1-for-20 reverse stock split and regained Nasdaq compliance in March 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315222012938/0001493152-22-012938-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315222012938/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-012938

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer